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Background: Non-muscle myosin IIA is involved 
in force generation, movement and membrane 
reshaping. Its activity is regulated by 
phosphorylation of the light chain. 
Results: NMHC-IIA head domain is tyrosine 
phosphorylated by Src and modulates Listeria 
intracellular levels. 
Conclusion: Tyrosine phosphorylation of NMHC-
IIA affects the outcome of infection.  
Significance: This novel post-translational 
modification of NMHC-IIA possibly affects its 
functions. 
 
SUMMARY 
Bacterial pathogens often interfere with 
host tyrosine phosphorylation cascades to 
control host responses and cause infection. 
Given the role of tyrosine phosphorylation 
events in different human infections and our 
previous results showing the activation of the 
tyrosine kinase Src upon incubation of cells 
with Listeria monocytogenes (Lm), we searched 
for novel host proteins undergoing tyrosine 
phosphorylation upon Lm infection. We identify 
the heavy chain of the non-muscle myosin IIA 
(NMHC-IIA) as being phosphorylated in a 
specific tyrosine residue in response to Lm 
infection. We characterize this novel post-
translational modification event and show that, 
upon Lm infection, Src phosphorylates NMHC-
IIA in a previously uncharacterized tyrosine 
residue (Y158) located in its motor domain near 
the ATP-binding site. In addition, we found that 
other intracellular and extracellular bacterial 
pathogens trigger NMHC-IIA tyrosine 
phosphorylation. We demonstrate that NMHC-
IIA limits intracellular levels of Lm and this is 
dependent on the phosphorylation of Y158. Our 
data suggest a novel mechanism of regulation of 
NMHC-IIA activity relying on the 
phosphorylation of Y158 by Src. 
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INTRODUCTION 
Listeria monocytogenes (Lm) is a human 
intracellular foodborne bacterial pathogen that 
causes serious disease in immunocompromised 
individuals. Within the host it finds suitable 
replication niches in the liver and spleen, 
disseminates and can reach the central nervous 
system. In pregnant women, Lm targets the fetus, 
eliciting fetal infection and abortions (1). The 
ability of Lm to cause disease relies on its capacity 
to invade nonphagocytic cells, replicate therein 
and spread to the entire organism overcoming the 
intestinal, blood-brain and fetoplacental barriers 
(2). Through the expression of bacterial factors Lm 
establishes a crosstalk with host cells favoring the 
progression of the cellular infection (3). In 
epithelial cells, Lm invasion is mainly driven by 
the bacterial surface proteins InlA and InlB that 
bind E-cadherin and c-Met, respectively, at the 
surface of host cells (4,5). This engagement of host 
cell receptors triggers tyrosine phosphorylation-
mediated signaling, resulting in the local activation 
of the Arp2/3 complex that initiates actin 
polymerization at the site of Lm attachment (6,7), 
causing membrane invagination that supports 
bacterial entry. InlB interaction with the receptor 
tyrosine kinase c-Met stimulates its auto-
phosphorylation, induces the tyrosine 
phosphorylation and recruitment of adaptor 
proteins, and the activation of phosphoinositide 3-
kinase (PI3K) (5,8,9). Phosphatidylinositol (3,4,5)-
triphosphate generated by PI3K accumulates at the 
cell membrane during Lm infection (8) and plays a 
crucial role in the recruitment of molecules 
controlling actin polymerization, such as Rac1 and 
WAVE2 (6,10-12). In turn, InlA binding to E-
cadherin induces the activation of Src tyrosine 
kinase that subsequently phosphorylates cortactin, 
E-cadherin and the clathrin heavy chain (7,13,14). 
While cortactin and clathrin tyrosine 
phosphorylations are critical events for actin 
polymerization and recruitment at the Lm entry site 
(7,13), E-cadherin phosphorylation leads to its 
ubiquitination, internalization and further 
degradation (14). The combined action of these 
events leads to the internalization the Lm into 
epithelial cells.  
In this study we aimed to identify new 
cellular proteins undergoing tyrosine 
phosphorylation in response to Lm infection and 
address whether such post-translational 
modification would regulate cellular infection. The 
tyrosine phosphorylated proteins were recovered 
from Lm-infected epithelial cells and subjected to 
mass spectrometry identification. We identified the 
non-muscle myosin heavy chain IIA (NMHC-IIA) 
as one of the enriched tyrosine phosphorylated 
proteins recovered upon Lm infection. 
NMHC-IIA is an actin-binding protein with 
motor and contractile properties, involved in 
cellular processes requiring force generation, cell 
movement and membrane reshaping (15). In 
infection, NMHC-IIA is critical for viral entry 
(16,17) and supports invasion (18) and 
dissemination (19) of various bacteria. While the 
serine/threonine phosphorylation of the regulatory 
light chain is a well-known mechanism to regulate 
non-muscle myosin IIA activity (15), our 
knowledge on the regulation of the heavy chain is 
limited and NMHC-IIA tyrosine phosphorylation 
has never been characterized. Here we show that 
NMHC-IIA undergoes tyrosine phosphorylation in 
response to several bacterial pathogens. Our data 
indicate that upon Lm cellular infection NMHC-
IIA was phosphorylated in tyrosine residue 158 by 
the host Src kinase. In the presence of blebbistatin, 
a chemical inhibitor of Myosin II activity, the 
percentage of cells showing Lm-associated actin 
foci was increased and correlated with higher 
levels of intracellular Lm. In addition, increased 
numbers of intracellular Lm were also found in 
cells depleted for NMHC-IIA as well as in 
conditions where NMHC-IIA tyrosine 
phosphorylation is prevented. These results show 
the involvement of NMHC-IIA in Lm infection 
and point to the regulatory role of its 
phosphorylation in tyrosine 158 which could affect 
NMHC-IIA activity. Our findings describe a novel 
post-translational modification of NMHC-IIA with 
important implications in bacterial infection. 
Taking into account the central role of NMHC-IIA 
in key cell biology processes, our data also suggest 
the existence of a new mechanism of NMHC-IIA 
regulation that could be of critical importance in 
the canonical functions of non-muscle Myosin IIA. 
 
EXPERIMENTAL PROCEDURES 
Bacterial strains and cell lines. Listeria and 
E. coli strains were grown aerobically at 37 ºC, 
with shaking, in brain-heart infusion (BHI) and 
Lysogeny Broth (LB) media, respectively. Yersinia 
was grown aerobically at 26 ºC, with shaking, in 
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LB media. When required antibiotics were added 
to growth media. Details are provided in Table 1. 
Caco-2 cells (ATCC HTB-37) were cultivated in 
MEM with L-glutamine, supplemented with non-
essential amino acids, sodium pyruvate, and 20% 
fetal bovine serum (FBS). HeLa (ATCC CCL-2), 
HEK293 (ATCC CRL-1573) and COS-7 (ATCC 
CRL-1651) cells were cultivated in DMEM with 
glucose (4.5 g/l) and L-glutamine, supplemented 
with 10% FBS. Cells were maintained at 37 ºC in a 
5% CO2-enriched atmosphere. Cell culture media 
and supplements were from Lonza. 
Plasmids, antibodies and reagents. Plasmids 
used are listed in Table 2. Plasmids GFP-NMHC-
IIA-Y158F and GFP-NMHC-IIA-Y190F were 
generated using GFP-NMHC-IIA-WT from 
Addgene (20) and the QuickChangeII XL site-
directed mutagenesis kit (Agilent Technologies). 
For NMHC-IIA rescue assays, a plasmid encoding 
siRNA-resistant GFP-NMHC-IIA-WT transcripts 
was generated. Oligonucleotide sequences are 
provided in Table 3. Antibodies are listed in Table 
4. F-actin was labeled with Alexa Fluor 647- or 
555-conjugated phalloidin (Invitrogen). Chemical 
inhibitors Y-26732 (Sigma-Aldrich), Blebbistatin 
and PP1 (Calbiochem) were handled as 
recommended. FluoSpheres-carboxylate modified 
microspheres were from Invitrogen (F-8814). 
Determination of intracellular bacteria. The 
levels of intracellular bacteria were determined as 
described (21). When indicated cells were 
incubated with serum-free medium containing 
blebbistatin, PP1 or DMSO. Cells were challenged 
with pre-washed Lm at a multiplicity of infection 
(MOI) of 50 or with Yp (MOI 10) for 60 min, 
treated with 20 µg/ml gentamicin for 90 min, 
washed in PBS, lysed with 0.2% Triton X-100 and 
serial dilutions were plated for CFU counting. For 
immunofluorescence scoring, cells infected with 
Lm (MOI 50) were treated with 100 µg/ml 
gentamicin for 10 min, and washed with 20 µg/ml 
gentamicin prior fixation. 
Immunoprecipitation assays. HeLa or Caco-2 
cells grown until confluence were washed twice 
with warm phosphate-buffered saline (PBS), 
serum-starved (5 h) and left non-infected (NI) or 
incubated with pre-washed Lm (21) at MOI 200 for 
different periods of time, or with E. coli (EPEC, 
EHEC or K12-inv strains) at MOI 200 for 4 h as 
described (22). When indicated, cells were treated 
with 10 µM PP1 or 50 µM Y-27632 30 min before 
infection. After washing twice with ice-cold PBS, 
cells were lysed in 1 ml of lysis buffer [1% Igepal 
CA-630 (Sigma-Aldrich), 50 mM Tris pH 7.5, 150 
mM NaCl, 2 mM EDTA, 1 mM AEBSF 
(Interchim), PhosSTOP and cOmplete Protease 
Inhibitor Cocktail (Roche Pharmaceuticals)] and 
lysates recovered after centrifugation (15,000 × g, 
15 min, 4 ºC). Cell lysates (500 µg) were 
incubated overnight (4 ºC) with 1 µg of anti-
phosphotyrosine 4G10 or 5 µg of anti-NMHC-IIA 
antibodies. Immune complexes were captured with 
50 µl of PureProteome Protein A or G magnetic 
beads (Millipore). Immunoprecipitated fractions 
were resolved by SDS-PAGE and gels were silver-
stained using the ProteoSilverTM Plus Silver 
Staining Kit (Sigma-Aldrich) or processed for 
immunoblotting. For kinase assay, HEK293 cells 
were harvested and lysed 24 h post-transfection, 
GFP fusion proteins were immunoprecipitated 
with anti-GFP conjugated agarose beads (sc-9996 
AC, Santa Cruz Biotechnology) and eluted in 0.2 
M glycine, pH 2.5. 
Protein identification by mass spectrometry 
(MS). Protein identification was performed by 
MALDI TOF/TOF mass spectrometry as described 
(23). Protein bands were excised from SDS-PAGE 
gels, reduced with dithiothreitol, alkylated with 
iodacetamide and in gel digested with trypsin. 
Peptides were extracted, desalted, concentrated 
using ZipTips (Millipore), crystallized onto a 
MALDI sample plate and analyzed using a 4700 
Proteomics Analyzer MALDI-TOF/TOF (Applied 
Biosystems). Peptidic mass spectra were acquired 
in reflector positive mode at a 700-4000 m/z mass 
window and proteins identified by Peptide Mass 
Fingerprint using the Mascot software (Matrix 
Science, UK) integrated in the GPS Explorer 
software (ABSCIEX, CA) and searched against the 
SwissProt/UniProt Homo sapiens protein sequence 
database. The maximum error tolerance was 35 
ppm and up to two missed cleavages were allowed. 
Phosphopeptide analysis by MS. Bands 
corresponding to NMHC-IIA, from anti-NMHC-
IIA IPs of NI and Lm-infected HeLa cells, were 
processed as described above. Phosphopeptides 
were selectively enriched by titanium dioxide 
chromatography (TiO2 Mag Sepharose, GE 
Healthcare). MALDI matrix used was THAP/DAC 
(2’,4’,6’-trihydroxyacetophenone monohydrate 9 
mg/mL, diammonium citrate 5 mg/mL, in 
water/Acetonitrile 50:50, v/v). Mass spectra were 
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acquired in a 4800 Plus MALDI TOF/TOF 
Analyzer mass spectrometer (AB SCIEX) both in 
reflector negative and MS/MS modes. 
Immunoblotting. Proteins were resolved in 
SDS-PAGE gels and transferred onto 
Nitrocellulose membranes (Hybond ECL, GE 
Healthcare Life Sciences). Membranes were 
blocked with 5% skimmed milk in buffer A (150 
mM NaCl, 20 mM Tris-HCl pH 7.4 and 0.1% 
Triton X-100) for 1 h at room temperature or 
overnight at 4ºC. Primary and secondary 
antibodies were diluted in 2.5% skimmed milk in 
buffer A. Membranes used for anti-
phosphotyrosine detection were blocked with 
Western Blocker solution (Sigma Aldrich), also 
used to dilute primary and secondary antibodies. 
Immunofluorescence analysis. Cells were 
fixed in 3% paraformaldehyde (15 min), quenched 
with 20 mM NH4Cl (1 h), permeabilized with 
0.1% Triton X-100 (5 min) and blocked with 1% 
BSA in PBS (30 min). Antibodies were diluted in 
PBS containing 1% BSA. Coverslips were 
incubated 1 h with primary antibodies washed 
three times in PBS and incubated 45 min with 
secondary antibodies and Phalloidin Alexa-555 or 
647. DNA was counterstained with DAPI (Sigma-
Aldrich). Coverslips were mounted onto 
microscope slides with Aqua-Poly/Mount (18606, 
Polysciences). Images were collected with a 
confocal laser-scanning microscope (Zeiss 
Axiovert LSM 510 or Leica SP2 AOBS SE) and 
processed using Adobe Photoshop software. 
Transfection and lentiviral transduction. The 
lentiviral shRNA expression plasmids Mission 
pLKO.1-puro (control) and Mission shRNA-cSrc 
(Sigma-Aldrich), were used in combination with 
the envelope plasmid pMD.G, and packaging 
plasmid pCMVR8.91. Packaging, envelope, and 
shRNA vector plasmids were co-transfected into 
HEK293 cells. Viral supernatants harvested after 
72 h, filtered and incubated with target HeLa cells 
for 48 h at 37°C. Puromycin was used to select for 
individual clones. The knock-down verified by 
immunoblot and/or real-time RT-PCR. 
Transfection of siRNA duplexes and plasmid 
DNA. HeLa cells seeded in 24- or 6-well plates 
were transfected with 60 nM of control siRNA-D 
(sc-44232 Santa Cruz Biotechnology) or specific 
siRNAs for NMHC-IIA or NMHC-IIB depletion, 
using Lipofectamine RNAiMax (Invitrogen) 
following manufacturer’s instructions. Assays 
were performed 48 h later. Sequences of siRNAs 
are provided in Table 4. For transient protein 
expression, HeLa cells were seeded in 24-well 
plates (1x105 cells/well), 6-well plates (4x105 
cells/well), or 10 cm dishes (3x106 cells/dish), and 
transfected at 90% confluency with 500 ng, 2.5 µg 
or 15 µg of plasmid DNA, respectively, using 
Lipofectamine 2000 (Invitrogen). Assays were 
performed 24 h later. For rescue assays, HeLa cells 
were transfected with NMHC-IIA-si#2 and 24 h 
later transiently transfected with plasmids 
encoding siRNA-resistant GFP-NMHC-IIA-WT. 
Kinase Assay. Kinase assays were performed 
using the Src Assay Kit (17-131, Millipore), 
following manufacturer’s instructions. Anti-GFP-
immunoprecipitated fractions from HEK293 cells 
expressing GFP-NMHC-IIA variants were 
incubated (10 min, 30 ºC) with 10 units of 
recombinant Src (14-117, Millipore), in 30 µl of 
kinase reaction buffer supplemented with 9 µl of 
Manganese/ATP Cocktail and 10 µCi γ 32P-ATP 
(PerkinElmer). Reactions including a Src-specific 
substrate or lacking Src were used as controls. 
Reactions were precipitated with 40% TCA and 
spotted onto P81 phosphocellulose paper squares, 
washed three times with 0.75% phosphoric acid, 
once with acetone and transferred to microtubes 
containing UniverSol liquid scintillation cocktail 
(MP Biomedicals). Incorporation of 32P was 
determined in a Wallac 1450 MicroBeta TriLux 
liquid scintillation counter (PerkinElmer), as 
counts per minute (cpm). Radioactivity 
measurements were performed in duplicate in two 
independent assays. 
Statistical analyses. Statistical analyses were 
performed with Prism 6 software (GraphPad 
Software, Inc.). One-way ANOVA with post hoc 
testing analyses were used for pair-wise 
comparison of means from at least three 
unmatched groups. Two-tailed Student's t-test was 
used to compare means of two samples and one-
sample t-test to compare with samples arbitrarily 
fixed to 100. Differences were not considered 
statistically significant for p value ≥ 0.05. 
 
RESULTS 
NMHC-IIA is tyrosine-phosphorylated in 
response to bacterial infection. To identify new 
host proteins undergoing tyrosine phosphorylation 
(pTyr) in response to Lm and which could affect 
Lm cellular infection, we compared the pTyr 
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protein profiles of Lm-infected and non-infected 
(NI) HeLa cells. Cell extracts were collected at 
different time points post inoculation and subjected 
to immunoprecipitation (IP) using anti-
phosphotyrosine antibodies (anti-pTyr). IP 
fractions were resolved by SDS-PAGE followed 
by silver staining. Bands showing variable 
intensities in Lm-infected versus NI cells were 
excised and processed for mass spectrometry 
identification. A band corresponding to a ≈250 
kDa protein and displaying increased intensity 
throughout the infection (Fig. 1A) was identified 
as the human non-muscle myosin heavy chain IIA 
(NMHC-IIA) (data not shown). 
To validate this result, HeLa and Caco-2 cells 
were incubated with Lm for different time periods 
and the presence of NMHC-IIA in anti-pTyr IP 
fractions was assessed by immunoblot using 
NMHC-IIA specific antibodies. We detected a 
time-dependent increase of NMHC-IIA in IP 
fractions from Lm-infected cells (Fig. 1B). Levels 
of NMHC-IIA in pTyr fraction increased 3.5-fold 
after 60 minutes of Lm incubation with HeLa cells 
and 15-fold in Caco-2 cells upon 20 minutes of Lm 
infection (Fig. 1B). Levels of NMHC-IIA in whole 
cell lysates (WCL) were not affected by infection 
(Fig. 1B), showing that increased levels of 
NMHC-IIA in IP samples are not related to an 
augmentation of NMHC-IIA expression. 
Incubation of HeLa cells with the non-pathogenic 
species Listeria innocua (Li) for 60 minutes only 
induced a small enrichment of NMHC-IIA in the 
anti-pTyr IP fractions as compared to Lm (Fig. 
1C). In addition, NMHC-IIA was barely detected 
in IP fractions from HeLa cells stimulated by E. 
coli DH5α  or latex beads (Fig. 1C). Altogether, 
these results indicate that the enrichment of 
NMHC-IIA in the pool of pTyr proteins is 
associated to the pathogenic features of Lm and is 
not a broad cellular response to any extracellular 
stimuli. 
To investigate whether the same response 
could be induced upon infection with other human 
bacterial pathogens, HeLa cells were incubated for 
4 h with: the extracellular pathogenic E. coli EPEC 
and EHEC; or the invasive E. coli K12 expressing 
the Yersinia pseudotuberculosis (Yp) invasin (K12-
inv) (24), an infection model allowing the study of 
signaling pathways triggered downstream the 
invasin-integrin interaction. As compared to NI 
conditions, NMHC-IIA appeared slightly increased 
in anti-pTyr IP fractions from EPEC- and EHEC-
infected cells. Strikingly, K12-inv induced a robust 
enrichment of NMHC-IIA in IP samples that is 
abolished in cells incubated with bacteria 
harboring a disrupted invasin-encoding gene (K12-
∆inv, Fig. 1D). For comparison cells were also 
incubated with Lm for 1 and 4 h (Fig. 1D). These 
results indicate that the enrichment of NMHC-IIA 
in the pool of pTyr proteins is an event triggered 
by several human bacterial pathogens. 
Our data suggest that bacterial infection either 
induces the direct NMHC-IIA pTyr or stimulates 
its interaction with a protein that undergoes itself 
pTyr. To address this issue, endogenous NMHC-
IIA was immunoprecipitated from NI and Lm-
infected HeLa cells and pTyr proteins were 
detected by immunoblot. A band showing a 
consistent 1.5-fold increase in intensity in infected 
samples was detected at the molecular weight of 
NMHC-IIA (Fig. 1E). Immunoprecipitated levels 
of NMHC-IIA were similar in NI and Lm-infected 
cells. These results support a direct pTyr of 
NMHC-IIA triggered by Lm infection. 
 
NMHC-IIA-pTyr induced by Lm cellular 
infection requires the activity of Src tyrosine 
kinase. Considering our previous findings 
revealing the key role of the tyrosine kinase Src 
during Lm invasion (7), we addressed the role of 
this kinase in NMHC-IIA-pTyr in the context of 
Lm infection. Prior to Lm incubation, HeLa cells 
were treated with PP1, an inhibitor of Src family 
kinases, or with Y-27632, an inhibitor of the 
serine/threonine kinase ROCK that regulates 
NMHC-IIA activity through the phosphorylation 
of the regulatory light chain of myosin II and 
limits Lm internalization (25). Given that NMHC-
IIA-pTyr is hardly detected by using anti-pTyr 
antibodies in immunoblot, cell lysates were 
subjected to anti-pTyr IP assay and NMHC-IIA 
was detected in IP fractions. The increase in 
NMHC-IIA-pTyr induced by Lm infection of non-
treated cells (NT) was abolished in PP1-treated 
cells while being not affected by Y-27632 
treatment (Fig. 2A), suggesting that NMHC-IIA-
pTyr requires Src kinase activity and occurs 
independently from ROCK activity. In addition, 
we interfered with Src activity by overexpressing a 
Src kinase-dead variant (Src-KD) (26). Levels of 
NMHC-IIA-pTyr induced by Lm infection were 
assessed in HeLa cells non-transfected (NT), 
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transfected with an empty plasmid (Ctr) or 
overexpressing Src-KD. In contrast to NT and Ctr 
cells showing increased levels of NMHC-IIA-pTyr 
upon Lm infection, in cells overexpressing Src-KD 
the NMHC-IIA-pTyr was almost undetectable 
(Fig. 2B). To further confirm these data, we 
targeted the expression of endogenous Src by 
using specific shRNAs. We observed that, Lm-
induced NMHC-IIA-pTyr occurred in shRNA 
control (sh Ctr) and was clearly diminished in 
shRNA Src expressing (sh Src) HeLa cells, in 
which Src expression is reduced by 60% (Fig. 2C 
and 2D). Altogether, these data demonstrate that 
Src activity is required for NMHC-IIA-pTyr 
triggered by bacterial infection. 
 
Host Src kinase phosphorylates NMHC-IIA in 
tyrosine residue 158. The NMHC-IIA amino acid 
sequence includes 34 tyrosine residues, most of 
which located in the myosin motor domain (Fig. 
3A). To identify the NMHC-IIA tyrosine residues 
phosphorylated by Src upon Lm infection, we used 
combined in silico approaches (NetPhos 2.0 and 
NetPhosK). Nine tyrosine residues were predicted 
as potentially phosphorylated, among which only 
the tyrosine in position 158 (Y158) was a putative 
substrate for Src kinase (Fig. 3B). To assess these 
in silico predictions and taking into account that 
Lm-induced NMHC-IIA-pTyr requires Src kinase 
activity (Fig. 2), we determined if NMHC-IIA-
pTyr occurs upon Lm infection of cells ectopically 
expressing either GFP-tagged NMHC-IIA-Y158F 
(in which Y158 residue was replaced by a 
phenylalanine), NMHC-IIA-Y190F (harboring the 
same amino acid substitution in position 190, 
randomly selected and unrelated to in silico 
predictions) or NMHC-IIA-WT (wild type 
NMHC-IIA). Lm infection of non-transfected 
(NT), NMHC-IIA-WT- and NMHC-IIA-Y190F-
overexpressing cells generated increased levels of 
NMHC-IIA-pTyr as compared to NI cells, while 
the overexpression of NMHC-IIA-Y158F largely 
limited Lm-induced NMHC-IIA-pTyr (Fig. 3C). 
Exogenous NMHC-IIA-WT and NMHC-IIA-
Y190F were occasionally detected in anti-pTyr IP 
fractions of Lm-infected cells (data not shown). 
Levels of endogenous NMHC-IIA were 
comparable in the different conditions and GFP 
fusion proteins were expressed similarly in NI and 
infected cells (Fig. 3C). These results corroborate 
in silico predictions and suggest the central role of 
Y158 in NMHC-IIA-pTyr triggered upon 
infection. To validate our results, total lysates from 
NI and Lm-infected cells were probed with an 
antibody raised against a peptide comprising 
phosphorylated Y158 residue of NMHC-IIA 
(pY158). In agreement with our data, levels of 
NMHC-IIA-pY158 were 1.5-fold increased in Lm-
infected cells (Fig. 3D). In addition, samples 
enriched in NMHC-IIA phosphopeptides from NI 
and Lm-infected cells were analyzed by mass 
spectrometry. A phosphopeptide spanning Y158 
(amino acid 142 to 165, 
KRHEMPPHIYAITDTAYRSMMQDR) was 
detected at m/z 3025.37 [M-H]- (Fig. 3E, cluster I) 
and at 3041.36 [M-H]- with an oxidized 
methionine (Fig. 3E, cluster II). In infected 
samples, the area of cluster I that is correlated with 
the abundance of the corresponding 
phosphopeptide, was 4.8-fold increased. Cluster II 
appeared 2.1-fold more abundant in Lm-infected 
samples as compared to NI. Cluster I was further 
characterized and validated by MS/MS 
sequencing. Altogether our data show that 
phosphorylation occurs in position Y158. 
We further evaluate whether NMHC-IIA-
pTyr occurs specifically on Y158 through Src 
activity, performing an in vitro kinase assay. GFP-
NMHC-IIA-WT or Y158F ectopically expressed 
in HEK293 cells were highly enriched through 
immunoprecipitation using an anti-GFP antibody 
and incubated with purified Src kinase and γ-32P-
ATP. A synthetic peptide substrate for Src was 
used as positive control. In the absence of kinase, 
the control peptide (Ctr) and IP fractions of 
NMHC-IIA-WT and Y158F showed residual 
levels of γ-32P-ATP incorporation. In the presence 
of Src kinase, the NMHC-IIA-WT enriched IP 
fraction and the control peptide became 
radiolabeled while the radioactivity incorporation 
in the NMHC-IIA-Y158F enriched sample 
remained at a basal level (Fig. 3F). 
Altogether these results strongly suggest that 
Y158 of NMHC-IIA is a substrate for Src kinase, 
becoming phosphorylated in response to Lm 
infection, and put forward the putative role of this 
event in cellular infection. In addition, Y158 
appears extremely conserved among species 
ranging from Saccharomyces cerevisiae to Homo 
sapiens (Fig. 3G), pointing the broad importance 
for Y158 in the regulation of highly conserved 
canonical functions of NMHC-IIA. 
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Inhibition of NMHC-IIA activity affects 
intracellular levels of Lm. To assess the role of 
NMHC-IIA activity in cellular infection, we 
measured intracellular levels of Lm following 
chemical inhibition of NMHC-IIA. Blebbistatin 
(Blebb), a specific inhibitor of myosin II activity 
(27), was added (10 or 100 µM) to HeLa and 
Caco-2 cells and Lm infection efficiency was 
quantified by gentamicin protection assays. As 
control we used an inactive form of blebbistatin 
[(+)Blebb]. Lm intracellular levels were increased 
by 2- to 8-fold, in a dose-dependent manner in 
both cell lines, following treatment with the active 
[(-)Blebb] as compared to the inactive enantiomer 
of blebbistatin (Fig. 4A). Untreated and inactive 
blebbistatin-treated cells showed similar levels of 
intracellular Lm (data not shown). Our data are in 
agreement with a previous report showing that 
blebbistatin treatment of L2 cells increases Lm 
adhesion and invasion (25). Recruitment of 
NMHC-IIA and formation of actin foci at Lm entry 
sites were both detected in control (DMSO) and 
active blebbistatin-treated (Blebb) HeLa cells (Fig. 
4B). While the percentage of Lm-associated cells 
remained similar in both conditions, the percentage 
of cells showing Lm-actin foci increased in the 
presence of active blebbistatin (Fig. 4C). Together, 
our results indicate that the ATPase activity of 
NMHC-IIA is not required for its localization to 
the sites of Lm uptake and does not influence the 
interaction of Lm with host cells. However, 
inhibition of NMHC-IIA ATPase activity fosters 
the formation of Lm-actin foci, which correlates 
with increased rates of intracellular bacteria. 
 
Reduced expression of NMHC-IIA increases 
the level of intracellular Lm. To further address the 
role of NMHC-IIA in Lm cellular infection, levels 
of adherent and intracellular Lm were quantified 
by gentamicin protection assays in NMHC-IIA-
depleted HeLa cells, using two siRNAs (si#1 and 
si#2). In accordance with data described above, 
levels of intracellular Lm increased 2-fold in 
NMHC-IIA-depleted (IIA-si#1 and IIA-si#2) as 
compared to control siRNA-transfected cells (Ctr) 
(Fig. 5A). NMHC-IIA depletion assessed by 
immunoblot reached 85% in si#1-transfected cells 
and 65% when using si#2 (Fig. 5A). Levels of 
adhered Lm were also augmented in NMHC-IIA-
depleted cells (data not shown). 
Immunofluorescence analysis of Lm-infected 
NMHC-IIA-depleted cells revealed a 2-fold 
increase in the percentage of cells associated to Lm 
and a 3-fold increase in the percentage of cells 
showing Lm-associated actin foci (Fig. 5B). The 
number of bacteria and actin foci per cell were also 
increased in NMHC-IIA-depleted cells (Fig. 5C), 
correlating with increased levels of intracellular 
bacteria. Our data indicate that, while Lm 
association to cells does not require NMHC-II 
activity it is modulated by NMHC-IIA itself 
probably through the interaction with other 
proteins. 
To discard the hypothesis that increased 
levels of intracellular Lm detected in NMHC-IIA-
depleted cells could result from the overexpression 
of the isoform B of non-muscle myosin heavy 
chain (NMHC-IIB), we confirmed that expression 
levels of NMHC-IIB were similar in NMHC-IIA-
depleted cells and control cells (Fig. 5D). In 
addition, we found that Lm intracellular levels 
decreased 3-fold in NMHC-IIB-depleted HeLa 
cells (Fig. 5E), suggesting that NMHC-IIA and IIB 
play opposite roles in Lm infection and thus 
undermining the possibility of their mutual 
functional replacement. To definitively reinforce 
our findings and exclude potential uncontrolled 
off-target effects, we performed gentamicin 
protection assays following gene rescue 
experiments. We created a siRNA-resistant GFP-
NMHC-IIA construct (NMHC-IIA-siRes) by 
introducing silent point mutations within the si#2 
target sequence. We found that increased levels of 
intracellular Lm detected upon NMHC-IIA 
depletion (IIA-si#2) dropped to control levels in 
NMHC-IIA-depleted cells expressing NMHC-IIA-
siRes (Fig. 5F). In contrast, the expression of 
NMHC-IIA-WT in NMHC-IIA-depleted cells did 
not restore control levels of intracellular Lm. 
Immunoblot analysis confirmed that the expression 
of endogenous NMHC-IIA was diminished in the 
presence of si#2 and that ectopically expressed 
NMHCH-IIA was only detected in NMHC-IIA-
siRes-transfected cells (Fig. 5F). However, in 
absence of si#2, both NMHC-IIA-WT and siRes 
variants are expressed at similar levels (Fig. 5G). 
Together these results confirm that the increase in 
Lm intracellular levels observed in NMHC-IIA-
depleted cells is specifically due to NMHC-IIA 
depletion. 
To analyze whether the role of NMHC-IIA on 
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intracellular levels of bacteria was specific for Lm 
or could be broadened to other bacterial infectious 
processes, we performed gentamicin protection 
assays using Li expressing InlB (Li-inlB), the 
major internalin driving Lm entry in HeLa cells 
(28); K12-inv and Yp. Numbers of intracellular Li-
inlB were not significantly different in NMHC-
IIA-depleted and Ctr cells (Fig. 5H). In contrast, 
levels of intracellular K12-inv and Yp were 
significantly lower in NMHC-IIA-depleted cells 
(Fig. 5H). Our data indicate that NMHC-IIA is 
specifically triggered by pathogenic Lm and is 
independent of an InlB-mediated uptake. By the 
contrary, the invasin-mediated uptake requires 
NMHC-IIA. Interestingly, NMHC-IIA and IIB 
were shown to be required for SopB-mediated 
invasion of Salmonella (18). Our findings, together 
with published reports, reveal that NMHC-IIA 
plays opposite roles in different infection models: 
while it is required for an utmost Yp and 
Salmonella infection, it has a restrictive role in Lm 
cellular infection. 
 
The function of NMHC-IIA in Lm infection 
relies on the phosphorylation of its tyrosine 158. 
We reported above two important observations: 1) 
NMHC-IIA is tyrosine phosphorylated by Src 
kinase upon Lm incubation with cells, and 2) Lm 
intracellular levels are increased in conditions of 
NMHC-IIA depletion or inhibition of its activity, 
demonstrating that NMHC-IIA activity limits Lm 
infection. To investigate whether both findings 
could be interconnected we evaluated levels of 
intracellular bacteria under conditions where 
NMHC-IIA-pTyr does not occur. We used cells 
with compromised Src activity (PP1 treatment and 
Src-KD overexpression) and cells expressing an 
NMHC-IIA non-phosphorylable variant (NMHC-
IIA-Y158F). Levels of intracellular Lm showed a 
2.5-fold increase in PP1-treated HeLa cells as 
compared to control DMSO-treated cells (Fig. 6A). 
In agreement, we observed an increase in Lm 
intracellular levels in cells expressing Src-KD 
(Fig. 6B). Inversely, intracellular levels of K12-inv 
decreased 2-fold in PP1-treated cells (Fig. 6C), as 
previously reported (29). Increased levels of 
intracellular Lm detected in conditions of Src 
inactivation and thus in absence of NMHC-IIA-
pTyr, correlates with our data showing that 
reduced levels or inactivation of NMHC-IIA 
resulted in increased numbers of intracellular Lm. 
Our data also suggest an association between the 
role of NMHC-IIA in Yp invasin-mediated uptake 
and invasin-triggered NMHC-IIA-pTyr. 
To further confirm the role of NMHC-IIA-
pTyr in the Lm cellular infection, we evaluated 
intracellular levels of Lm in HeLa and COS-7 cells 
transiently expressing either the GFP-NMHC-IIA-
WT (WT) or the non-phosphorylable variant GFP-
NMHC-IIA-Y158F (Y158F). Contrarily to HeLa 
cells, COS-7 cells naturally lack NMHC-IIA 
expression, therefore allowing the overcoming of 
effects from the endogenous protein. Equivalent 
expression levels of both constructs were verified 
by flow cytometry and immunoblot (data not 
shown). Lm intracellular rates were determined by 
gentamicin protection assays in cell populations 
containing about 50% of transfected cells. As 
compared to NMHC-IIA-WT, the expression of 
NMHC-IIA-Y158F led to increased levels of 
intracellular Lm in both cell lines (Fig. 6D). Thus, 
NMHC-IIA-Y158F expression recapitulates the 
increase of intracellular Lm in NMHC-IIA-
depleted or inactivated cells. Furthermore, both 
GFP-NMHC-IIA-WT and GFP-NMHC-IIA-
Y158F showed the same localization and 
accumulate at the site of Lm entry in HeLa cells 
(Fig. 6E). These results indicate that, whereas 
NMHC-IIA subcellular localization and 
recruitment to the site of bacterial uptake are 
unrelated to Y158, the phosphorylation of this 
specific NMHC-IIA tyrosine plays a key role in 
restraining Lm infection. 
 
DISCUSSION 
Pathogens interfere with host phosphorylation 
cascades to foster adhesion, invasion and 
intracellular survival. Here, we searched for new 
host proteins undergoing tyrosine phosphorylation 
upon Lm infection. We showed that NMHC-IIA is 
tyrosine phosphorylated in response to Lm as well 
as to other human bacterial pathogens such as 
EPEC, EHEC and K12-inv. In Lm infection, this 
previously unknown tyrosine phosphorylation 
event is triggered by Src kinase on residue Y158 of 
NMHC-IIA, and limits intracellular bacterial 
levels. 
Myosin II activity is regulated by 
phosphorylation events in serine and threonine 
residues of the regulatory light chain (15). NMHC-
IIA also undergoes serine and threonine 
phosphorylations, which regulate the assembly of 
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myosin II filaments in vitro and are thought to 
control subcellular localization of NMHC-IIA and 
contractility that depends on the actin-crosslinking 
activity of NMHC-IIA (15). While NMHC-IIA 
was detected in studies aiming to unravel the 
global phosphotyrosine signaling in cancer tissues 
(30,31), its tyrosine phosphorylation has never 
been characterized. Our data constitutes the first 
report showing and characterizing NMHC-IIA-
pTyr. Our preliminary in silico analysis suggest an 
important and broad role for NMHC-IIA pTyr in 
position 158: 1) Y158 is highly conserved among 
species ranging from Saccharomyces cerevisiae to 
Homo sapiens, 2) an in silico study suggested that 
the residue Y163 of muscle myosin heavy chain 
(matching Y158 in NMHC-IIA) could be 
phosphorylated (32), 3) Y158 is located in the 
motor domain of NMHC-IIA nearby the ATP-
binding pocket and 4) analysis of the crystal 
structure of myosin motor domain (33) showed 
that Y158 is exposed at the surface of the protein 
and is thus accessible for phosphorylation. Thus, 
we hypothesize that the phosphorylation of 
NMHC-IIA Y158 could modulate NMHC-IIA 
activity most probably by affecting its ability to 
bind and/or hydrolyze ATP. However at this point 
any other mechanism could be envisaged. In 
addition it is likely that NMHC-IIA-pTyr in Y158 
occurs in specific physiological conditions 
engaging NMHC-IIA activity and thus plays a role 
in the regulation of the highly conserved canonical 
functions of NMHC-IIA. The functional and 
structural outcomes of such modification are now 
critical to elucidate. 
Our data suggest that, upon infection, only a 
small pool of NMHC-IIA becomes phosphorylated 
in Y158, probably concentrated in a restricted 
subcellular localization and/or interacting with 
specific partners, which would impact infection. 
Yet, we observed that both NMHC-IIA-WT and 
Y158F concentrated around bacteria at the entry 
site. We also found that phosphorylation of Y158 
does not affect the phosphorylation of the myosin 
regulatory light chain (our unpublished data), that 
is achieved by MLCK and is required for 
activation of myosin II motor activity (15). 
Interestingly, Src was previously shown recruited 
to membrane blebs where it associates with MLCK 
and myosin II (34,35). In response to cell swelling, 
Src and MLCK form a complex in which Src 
activates MLCK and both regulate a compensatory 
membrane retrieval that requires myosin II (35). It 
is thus conceivable that Src and MLCK could work 
together to fine-tune the activity of myosin II in 
the context of infection. 
Myosin II isoforms were recently involved in 
viral and bacterial infections either promoting or 
limiting pathogen progression. However their role 
in such processes is still mainly descriptive. 
NMHC-IIA is required for KSHV and HSV1 entry 
into cells (16,17,36), facilitates Salmonella 
invasion and regulates its intracellular growth 
(18,37) and promotes Chlamydia dissemination 
(19). Conversely, myosin II limits bacterial cell-to-
cell spread by restraining Lm protrusion formation 
(38) and participating in the formation of Shigella-
associated septin cages (39). NMHC-IIB is 
involved in the formation of actin-rich structures 
that accumulate near the Salmonella-containing 
vacuole and restrain bacterial intracellular 
multiplication (40). Altogether, these data suggest 
that the different outcomes associated with myosin 
II function during infection are probably related to 
the cellular machinery engaged in the various 
infectious processes. Our results indicate that 
NMHC-IIA activity limits Lm infection most 
probably hindering cellular invasion by interfering 
with the formation of Lm-induced actin foci. 
NMHC-IIA-depleted or inactivated cells were 
reported to lose cytoplasm cohesion and show 
increased membrane activity and plasticity (41,42). 
These phenotypes could thus suggest that the 
increased numbers of intracellular Lm observed in 
such cells would be greatly due to the disruption 
membrane rigidity. However, if this was the case, 
cells displaying low NMHC-IIA activity should be 
more permissive to any extracellular pathogen, 
which was not observed in KSHV (17), HSV1 (16) 
and Salmonella (18) infections. In addition, we 
show here that NMHC-IIA sustains invasin-
mediated Yp infection and the invasion rate of Li 
expressing InlB was not significantly increased by 
NMHC-IIA-depletion, thus excluding a non-
specific cell invasion mechanism. 
NMHC-IIA participates in cellular processes 
associated to phosphotyrosine signaling, which are 
largely usurped by bacteria, namely Lm and Yp 
(43), during infection. It 1) regulates protrusion 
formation and cell migration through the 
generation of actin retrograde flow (44,45), 2) is 
required for integrin-mediated adhesion maturation 
(46), 3) controls cell-cell adhesion promoting E-
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cadherin clustering and stabilizing cellular 
junctions (47), and 4) it governs the polarization of 
epithelial cells generating forces to maintain the 
epithelia (48). Whether NMHC-IIA is pTyr in 
these processes is unknown. 
In intercellular junctions, NMHC-IIA is 
critical for the E-cadherin localization (47) and Src 
activation is required for actin polymerization at 
cell-cell contacts (49), as it is during E-cadherin-
mediated Lm invasion (7). Interestingly, Src 
activation and recruitment of c-Cbl are key events 
to control c-Met signaling (50). Our data show that 
Src activity restricts intracellular levels of Lm in 
HeLa cells in which Lm uptake is mainly mediated 
by c-Met and rise the hypothesis that Src is acting 
through the tyrosine phosphorylation of NMHC-
IIA to inhibit entry. Remarkably, in KSHV 
infection, which depends on integrin and Src 
activation (51), NMHC-IIA interacts with the 
ubiquitin ligase c-Cbl (17). The complex c-Cbl- 
NMHC-IIA associates with the receptor tyrosine 
kinase EphA2 that amplifies Src signaling to 
promote viral macropinocytosis (36). It is thus 
possible that c-Cbl, which is required for Lm 
infection (52), associates with NMHC-IIA and c-
Met to modulate Lm infection through tyrosine 
phosphorylation events. To invade cells, Yp binds 
β1-integrin (53), which via its cytoplasmic tail 
interacts with NMHC-IIA to regulate cell 
migration (54). As in adhesion and cell migration 
processes (55), during Yp infection the engagement 
of β1-integrin leads to the activation of Src kinase 
(56) that could also act on NMHC-IIA triggering 
its tyrosine phosphorylation at the site of bacterial 
attachment thereby promoting Yp infection. 
Our data open new perspectives in the 
regulatory mechanisms governing NMHC-IIA 
functions in infection and physiological cellular 
processes. Further work should reveal whether 
NMHC-IIA-pTyr affects its motor activity, binding 
partners and/or the formation of actomyosin 
filaments. 
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FIGURE LEGENDS 
Figure 1. NMHC-IIA is tyrosine-phosphorylated in response to human bacterial pathogens. (A) 
Silver-stained acrylamide gel showing the tyrosine phosphorylation profiles of non-infected (NI) and Lm-
infected HeLa cells, for the indicated periods of time. Total tyrosine-phosphorylated proteins were 
immunoprecipitated with an anti-pTyr antibody. Molecular weight standards are indicated. Arrow shows a 
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protein band with increased intensity over the time of infection and identified by mass spectrometry 
analysis as NMHC-IIA. (B) HeLa and Caco-2 cells were left non-infected (NI) or incubated with Lm and 
harvested at indicated time points post-infection (p.i.). Tyrosine-phosphorylated proteins were 
immunoprecipitated (IP: pTyr) from whole cell lysates (WCL) and NMHC-IIA was detected by 
immunoblot (NMHC-IIA) in IP fractions and WCL. Detection of actin protein levels served as loading 
control. Bottom panels show quantifications of NMHC-IIA signals from at least 3 independent 
experiments in WCL and IP fractions of NI and Lm-infected HeLa (60 min p.i.) and Caco-2 (20 min p.i.) 
cells. (C) HeLa cells were left NI or incubated with either Lm, L. innocua (Li) (top panels), E. coli DH5α 
(Ec) or latex beads (bottom panels). Tyrosine-phosphorylated proteins were immunoprecipitated from 
WCL recovered at different time points and NMHC-IIA was analyzed by immunoblot in IP fractions and 
WCL. (D) HeLa cells were left NI or incubated, for 4 h, with pathogenic E. coli (EPEC and EHEC) and E. 
coli K12 expressing a functional (inv) or mutated variant (∆inv) of Y. pseudotuberculosis invasin. Cells 
were also incubated with Lm for 1 and 4 h (right panel). Tyrosine-phosphorylated proteins were 
immunoprecipitated and NMHC-IIA detected by immunoblot in IP fractions and WCL. Quantifications of 
NMHC-IIA signals for each IP fraction related to WCL are indicated (ratio). Values represent the mean of 
three independent experiments. (E) NMHC-IIA was immunoprecipitated (IP: NMHC-IIA) from WCL of 
NI and Lm-infected (Inf, 60 min) HeLa cells. Tyrosine-phosphorylated proteins (pTyr) and NMHC-IIA 
were detected in immunoprecipitates. As control, NMHC-IIA and actin were also detected in WCL. 
 
Figure 2. The activity of Src kinase is required for NMHC-IIA tyrosine phosphorylation upon Lm 
cellular infection. (A) HeLa cells pre-treated with PP1 (10 µM) or Y-27632 (50 µM) during 30 min, were 
left NI or incubated with Lm for 1 h (Inf) in the presence of the same concentrations of drugs. Non-treated 
(NT) HeLa cells were used as control. (B) HeLa cells non-transfected (NT), transfected with a control 
empty plasmid (Ctr) or with a Src kinase dead (Src-KD)-encoding plasmid. (C) HeLa cells stably 
expressing an shRNA control (sh Ctr) or a specific shRNA targeting Src expression (sh Src). Cells in B 
and C were left NI or incubated with Lm for 1 h (Inf). In A, B and C, total tyrosine-phosphorylated 
proteins were immunoprecipitated and NMHC-IIA was detected by immunoblot in IP fractions and WCL. 
Detection of actin levels served as loading control. Src protein levels were also confirmed by immunoblot. 
(D) Efficiency of Src depletion in sh Src HeLa cells was assessed by immunoblot using actin protein 
detection as loading control (left panel) and by qRT-PCR (right panel). Src mRNA expression is 
represented relative to the expression of control HPRT1. In sh Ctr cells, the relative expression was 
arbitrarily fixed to 1. 
 
Figure 3. NMHC-IIA tyrosine residue in position 158 is phosphorylated in response to Lm infection. 
(A) Schematic representation of NMHC-IIA showing the distribution of tyrosine residues (red bars). 
Tyrosine residues in position 158 (Y158) and 190 (Y190) are highlighted. ATP-binding site, motor and 
tail domains are indicated. (B) In silico predictions obtained from NetPhos 2.0 and NetPhosK servers, for 
tyrosine phosphorylation potential (score) and putative kinase involved. The position and amino acid 
environment of tyrosine residues showing a phosphorylation potential above the threshold (score >0.5) are 
indicated. (C) HeLa cells expressing the wild type GFP-NMHC-IIA (WT) and the mutants GFP-NMHC-
IIA-Y158F (Y158F) or GFP-NMHC-IIA-Y190F (Y190F) were left NI or incubated with Lm for 1 h (Inf). 
NMHC-IIA was detected by immunoblot in anti-pTyr immunoprecipitates and WCL. Detection of GFP 
indicates similar expression levels of NMHC-IIA constructs and actin levels served as loading control. (D) 
HeLa cells were left NI or incubated with Lm for 1 h (Inf). Total cell extracts were used in immunoblot 
using an antibody raised against NMHC-IIA-pY158. Total levels of NMHC-IIA were detected using an 
anti-NMHC-IIA antibody and α-tubulin levels were used as loading control. Bottom panel show 
quantification of NMHC-IIA-pY158 signals from 3 independent experiments in NI and Lm-infected HeLa 
cells. (E) Mass spectra from NMHC-IIA acquired after phosphopeptide enrichment from NI and Inf HeLa 
cells. Two peak clusters marked as I (monoisotopic peak at m/z 3025.37 [M-H]-) and II (monoisotopic 
peak at m/z 3041.36 [M-H]- with oxidized methionine) were detected. The corresponding NMHC-IIA 
peptide (aa 142 to 165) is indicated and Y158 highlighted. The area of the clusters in NI and Inf 
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conditions is indicated between parentheses. (F) Anti-GFP IP fractions obtained from WCL of HEK293 
cells expressing either GFP-NMHC-IIA-WT (WT) or GFP-NMHC-IIA-Y158F (Y158F) were used in in 
vitro Src kinase assays. A synthetic peptide was used as positive control (Ctr). Incorporation of 
radiolabeled γ-32P-ATP was measured in CPM (counts per minute) for each condition. Results are 
representative of two independent experiments. (G) Comparative analysis of the NMHC-IIA amino acid 
sequence from different species, focused in the region encompassing the tyrosine on position 158. 
 
Figure 4. Lm intracellular levels increased upon inhibition of NMHC-IIA activity. (A) Levels of 
intracellular Lm were assessed by gentamicin protection assay and CFU counting, in HeLa and Caco-2 
cells treated with 10 or 100 µM blebbistatin (Blebb). Graph shows the fold-increase of intracellular Lm 
determined as the ratio of intracellular bacteria in cells treated with the active versus the inactive 
enantiomer of blebbistatin. (B) Single confocal sections of HeLa cells infected with Lm in the presence of 
DMSO (control) or 50 µM active Blebbistatin. Infected cells were immunolabelled for NMHC-IIA (green) 
and Lm (blue) and stained for actin (red). (C) Immunofluorescence scoring of DMSO- and active 
Blebbistatin-treated HeLa cells associated to Lm and showing Lm-associated actin foci. Results are 
means±SD from three independent experiments, each done in duplicate. Statistically significant 
differences are indicated: * p<0.05. 
 
Figure 5. Depletion of NMHC-IIA facilitated Lm cellular infection. (A) Intracellular levels of Lm 
assessed by gentamicin protection assay in HeLa cells non-transfected (NT) or transfected with either 
control siRNA (Ctr) or NMHC-IIA-specific siRNAs (si#1 and si#2). Efficiency of NMHC-IIA 
knockdown was assessed by immunoblot and quantified. Indicated values (Normalized expression) are 
relative to actin and NMHC-IIA expression levels in NT cells. (B) Percentage of control (Ctr) or NMHC-
IIA-depleted cells (IIA-si#1) associated to Lm and showing Lm-associated actin foci, evaluated by 
immunofluorescence scoring. (C) Number of bacteria and actin foci per cell in control and NMHC-IIA-
depleted conditions. (D) Depletion of NMHC-IIA does not affect the expression of NMHC-IIB. NMHC-
IIB expression levels were evaluated by immunoblot in NMHC-IIA-depleted (IIA-si#1) as compared to 
control (NT and Ctr) cells. Actin was used as loading control. (E) Intracellular levels of Lm were assessed 
by gentamicin protection assay in HeLa cells transfected with either control siRNA (Ctr) or NMHC-IIB-
specific siRNA (IIB-si). Efficiency of NMHC-IIB knockdown was assessed by immunoblot using actin 
protein detection as loading control. (F) Expression of NMHC-IIA was restored in si#2-depleted cells 
through the expression of a siRNA-resistant GFP-NMHC-IIA (NMHC-IIA-siRes). Intracellular levels of 
Lm assessed by gentamicin protection assay in HeLa cells expressing different levels of NMHC-IIA are 
shown. Non-treated and NHMC-IIA-depleted cells expressing a wild type GFP-NMHC-IIA (NMHC-IIA-
WT) were used as controls. Endogenous NMHC-IIA silencing and GFP-NMHC-IIA expression was 
evaluated by immunoblot. Detection of actin levels served as loading control. (G) Western blot showing 
expression levels of endogenous (anti-NMHC-IIA, M8064, Sigma-Aldrich) and ectopically expressed 
NMHC-IIA (anti-GFP, B2, Santa Cruz Biotech) in HeLa cells transfected either with GFP-NMHC-IIA-
WT or GFP-NMHC-IIA-siRes expression vectors. (H) Intracellular levels of L. innocua expressing inlB 
(Li-inlB), E. coli K12 expressing the invasin (K12-inv) and Y. pseudotuberculosis (Yp) were assessed by 
gentamicin protection assay in HeLa cells transfected with either control siRNA (Ctr) or NMHC-IIA-
specific siRNA (IIA-si#1). In panels A and F, the number of intracellular Lm in NT cells was normalized 
to 100% and those in siRNA-transfected cells were expressed as relative values to NT cells. In panels E 
and H, numbers of intracellular bacteria were normalized to 100% in Ctr cells and expressed as relative 
values in the other conditions. Results shown in panels A, B, C, E, F and H are means±SEM of at least 
three independent experiments, each done in triplicate. Statistically significant differences are indicated: * 
p<0.05, ** p<0.01 and *** p<0.001.  
 
Figure 6. NMHC-IIA phosphorylation in tyrosine 158 is required to limit Lm cellular infection. (A 
and B) Intracellular levels of Lm assessed by gentamicin protection assays in the presence of 10 µM PP1 
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(A) or in HeLa cells expressing Src-KD (B). (C) Levels of intracellular K12-inv were assessed by 
gentamicin protection assay in HeLa cells treated with 10 µM of PP1. (D) Intracellular levels of Lm were 
assessed by gentamicin protection assays in HeLa and COS-7 cells expressing either GFP-NMHC-IIA-
WT (WT) or GFP-NMHC-IIA-Y158F (Y158F). Results shown in panels A, B, C and D are means±SEM 
of three independent experiments, each done in triplicate Numbers of intracellular bacteria were 
normalized to 100% in control cells and expressed as relative values in the other experimental conditions. 
Statistically significant differences are indicated: * p<0.05, ** p<0.01. (E) Single confocal section of 
COS-7 cells ectopically expressing either GFP-NMHC-IIA-WT or Y158F variants incubated with Lm for 
1 h and stained for actin (phalloidin, red) and DNA (DAPI, blue) (scale bar 10 µm). 
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Table 1. List of bacterial strains used in this study and the corresponding growth conditions. 
 
 
 
 
 
 
 
 
 
 
 
Table 2. List of plasmids used in this study. 
 
 
 
 
 
 
 
 
Table 3. List of antibodies used in this study. 
 
Antigen Species Applications Reference Source 
Phosphotyrosine Mouse IP (1:300) WB (1:1000) 4G10, 05-321 Millipore 
Phosphotyrosine Mouse WB (1:1000) PY20, P4110 Sigma-Aldrich 
Actin Mouse WB (1:5000) AC-15, A5441 Sigma-Aldrich 
NMHC-IIA Mouse IF (1:1000) ab55456 Abcam 
GFP Mouse IP (1:100) WB (1:500) B2, sc-9996 
Santa Cruz 
Biotechnology 
NMHC-IIA pY158 Rabbit WB (1:500) AP3775a Abgent 
Listeria Rabbit IF (1:200) ab35132 Abcam 
NMHC-IIA Rabbit IP (1:100) WB (1:5000) M8064 Sigma-Aldrich 
c-Src Rabbit WB (1:500) GD11, 05-184 Millipore 
c-Src Rabbit WB (1:1000) ab109381 Abcam 
NMHC-IIB Rabbit WB (1:1000) M7939 Sigma-Aldrich 
Anti-rabbit or anti-mouse 
HRP Goat WB 
BI2413C 
BI2407 PARIS 
Anti-rabbit or anti-mouse 
Alexa Fluor 488 Goat IF 
A11034 
A11001 Invitrogen 
Anti-rabbit or anti-mouse 
Cy3 Goat IF 
111-165-144 
115-165-146 
Jackson 
ImmunoResearch 
Anti-rabbit or anti-mouse 
Cy5 Goat IF 
111-175-144 
115-175-146 
Jackson 
ImmunoResearch 
 
 
 
 
 
 
 
 
 
 
 
Bacterial strains Growth Media T (°C) 
L. monocytogenes (EGDe) BHI (Difco Laboratories) 37 
L. innocua (CLIP 11262) BHI 37 
L. innocua-inlB BHI Erythromycin 5µg/ml 37 
E. coli DH5α LB (Difco Laboratories) 37 
EPEC LB Ampicilin 100 µg/ml (Amp100) 37 
EHEC LB  37 
E. coli K12-inv LB Amp100 37 
E. coli K12-Δinv LB Amp100 37 
Y. pseudotuberculosis LB Amp100 26 
Plasmid Description Source 
GFP-NMHCIIA-WT pEGFP-C3:CMV-GFP-NMHC IIA Addgene (#11347) 
GFP-NMHCIIA-Y158F pEGFP-C3:CMV-GFP-NMHC IIA (Y158F) This study 
GFP-NMHCIIA-Y190F pEGFP-C3:CMV-GFP-NMHC IIA (Y190F) This study 
GFP-NMHCIIA-WT-siRes pEGFP-C3:CMV-GFP-NMHC IIA siRNA resistant This study 
Src-KD pcDNA3-Src Kinase Dead (A430V) Sarah J. Parsons, Univ. of Virginia  
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Table 4. Sequences of siRNA duplexes, shRNAs and primers used in this study. 
 
 
 
siRNA duplexes 
Name Oligo Sequence (5’-3’) Source 
NMHCIIA-si#1 
(Pool of 3 siRNAs) 
 
A Sense: CAUCUACUCUGAAGAGAUUtt 
Santa Cruz Biotechnology 
(#sc-61120) 
Antisense: AAUCUCUUCAGAGUAGAUGtt 
B Sense: GAAGAUCAAUCCAUCUUGUtt Antisense: ACAAGAUGGAUUGAUCUUCtt 
C Sense: CCAAAGAGAACGAGAAGAAtt Antisense: UUCUUCUCGUUCUCUUUGGtt 
NMHCIIA-si#2 Sense: GAAGAUCAAUCCAUCUUGUtt Santa Cruz Biotechnology 
(#sc-61120B) Antisense: ACAAGAUGGAUUGAUCUUCtt 
NMHCIIB-si Sense: GCAAUACAGUGGGACAGUUtt Sigma-Aldrich 
(#00072460) Antisense: AACUGUCCCACUGUAUUGCtt 
shRNAs Sequence (5’-3’) and Source 
Src CCGGGTGGCTTACTACTCCAAACATCTCGAGATGTTTGGAGTAGTAAGCCACTTTTT Sigma-Aldrich (TRCN0000023597) 
Control CCGGGCGCGATAGCGCTAATAATTTCTCGAGAAATTATTAGCGCTATCGCGCTTTTT Sigma-Aldrich (SHC016) 
Primers sequences (5’-3’) 
NMHC-IIA-
Y158F 
Fw: CTATGCCATCACAGACACCGCCTTCAGGAGTATGATGCAAGAC 
Rev: GTCTTGCATCATACTCCTGAAGGCGGTGTCTGTGATGGCATAG 
NMHC-IIA-
Y190F 
Fw: CACCAAGAAGGTCATCCAGTTTCTGGCGTACGTGGCGTCTCG 
Rev: CGAGGACGCCACGTACGCCAGAACTGGATGACCTTCTTGGTG 
NMHC-IIA-WT-
siRes 
Fw: GATGCAAGACCGAGAGGATCAATCCATACTGTGCACTGGTGAATC 
Rev: GATTCACCAGTGCACAGTATGGATTGATCCTCTCGGTCTTGCATC 
c-Src Fw: CTGTTCGGAGGCTTCAACTC Rev: CCACCAGTCTCCCTCTGTGT 
HPRT1 Fw: GGCGTCGTGATTAGTGATG Rev: CACCCTTTCCAAATCCTCAG 
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